Showing results (491-500 of 548) with videos related to
Sort By:
Pageof 55
American Journal of Hematology|March 15, 2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403Lawrence D Kaplan, Matthew J Maurer, Wendy Stock, et al.Cancer Discovery|February 5, 2021
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental SignaturesNikita Kotlov, Alexander Bagaev, Maria V Revuelta, et al.The Lancet. Oncology|November 25, 2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H Wilson, Owen A O'Connor, Myron S Czuczman, et al.Leukemia & Lymphoma|July 9, 2025
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201Charalambos Andreadis, Olivia Bobek, Eric D Hsi, et al.Cancer Research|September 4, 2021
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell LymphomasM Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responsesCharles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.Eclinicalmedicine|December 16, 2024
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trialJonathan W Friedberg, Michael T Brady, Myla Strawderman, et al.Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.Pageof 55